AppLovin has already minted fortunes for early believers, but a brutal year-to-date selloff and a corporate transformation ...

The stock has surged 160% over the past three years. Meanwhile, two key drugs could continue driving rampant growth.

The stock has soared 400% in recent years.

More than just a simple rise, the pharmaceutical company's stock has been re-evaluated due to a growth narrative that continues to expand.